
VSTM
Verastem Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.300
Open
5.070
VWAP
5.08
Vol
1.81M
Mkt Cap
289.58M
Low
4.870
Amount
9.18M
EV/EBITDA(TTM)
--
Total Shares
25.33M
EV
241.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Show More
9 Analyst Rating

189.37% Upside
Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.25 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy

189.37% Upside
Current: 5.270

Low
12.00
Averages
15.25
High
20.00

189.37% Upside
Current: 5.270

Low
12.00
Averages
15.25
High
20.00
RBC Capital
Outperform
to
NULL
downgrade
$16 -> $12
2025-06-25
Reason
RBC Capital
Price Target
$16 -> $12
2025-06-25
downgrade
Outperform
to
NULL
Reason
RBC Capital lowered the firm's price target on Verastem to $12 from $16 and keeps an Outperform rating on the shares. The firm is updating its model after the approval of Av-Fak, ASCO data for Av-Fak in PDAC, and data from partnered G12D, the analyst tells investors in a research note. RBC adds that it sees significant upside in the pipeline, with potential for label expansions into PDAC or NSCLC.
H.C. Wainwright
Sean Lee
Buy
upgrade
$10 -> $14
2025-05-09
Reason
H.C. Wainwright
Sean Lee
Price Target
$10 -> $14
2025-05-09
upgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Verastem to $14 from $10 and keeps a Buy rating on the shares after the company's avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
RBC Capital
Gregory Renza
Outperform
maintain
$14 -> $16
2025-05-09
Reason
RBC Capital
Gregory Renza
Price Target
$14 -> $16
2025-05-09
maintain
Outperform
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on Verastem to $16 from $14 and keeps an Outperform rating on the shares. The approval of Avmapki Fakzynja Co-Pack has transformed Verastem into a commercial-stage company with the first FDA-approved drug in LGSOC, low-grade serous ovarian cancer, and the launch blueprint with key strategic imperatives and a pricing model are well-thought-out and supported by reasonable analogs, the analyst tells investors in a research note.
Jefferies
Kelly Shi
Buy
maintain
$15 -> $19
2025-05-08
Reason
Jefferies
Kelly Shi
Price Target
$15 -> $19
2025-05-08
maintain
Buy
Reason
Jefferies
Kelly Shi
Strong Buy
Initiates
$15
2025-04-10
Reason
Jefferies
Kelly Shi
Price Target
$15
2025-04-10
Initiates
Strong Buy
Reason
Mizuho
Mara Goldstein
Buy
Maintains
$9 → $8
2025-04-09
Reason
Mizuho
Mara Goldstein
Price Target
$9 → $8
2025-04-09
Maintains
Buy
Reason
Mizuho analyst Graig Suvannavejh yesterday lowered the firm's price target on Verastem to $8 from $9 and keeps an Outperform rating on the shares. The firm updated the company's model ahead of an expected product launch for avutometinib plus defactinib in low grade serous ovarian cancer.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Verastem Inc (VSTM.O) is -1.82, compared to its 5-year average forward P/E of -5.33. For a more detailed relative valuation and DCF analysis to assess Verastem Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.33
Current PE
-1.82
Overvalued PE
2.15
Undervalued PE
-12.81
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.42
Undervalued EV/EBITDA
-0.75
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
656.38
Current PS
9.56
Overvalued PS
2436.77
Undervalued PS
-1124.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+57.43%
-44.17M
Operating Profit
FY2025Q1
YoY :
+53.86%
-52.10M
Net Income after Tax
FY2025Q1
YoY :
-23.81%
-0.96
EPS - Diluted
FY2025Q1
YoY :
+36.53%
-38.68M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
693.0K
USD
9
3-6
Months
13.3K
USD
6
6-9
Months
56.4K
USD
11
0-12
Months
5.3K
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
7.7K
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1120.13% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
1
6-9
Months
643.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
4.8M
Volume
Months
6-9
1
397.5K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
693.0K
USD
9
3-6
Months
13.3K
USD
6
6-9
Months
56.4K
USD
11
0-12
Months
5.3K
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
7.7K
USD
Months
VSTM News & Events
Events Timeline
2025-07-11 (ET)
2025-07-11
16:26:53
Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology

2025-06-30 (ET)
2025-06-30
16:02:58
Verastem announces Nature Medicine publication of FRAME results

2025-06-24 (ET)
2025-06-24
16:04:10
Verastem announces first patient dosed with VS-7375

Sign Up For More Events
Sign Up For More Events
News
9.0
07-11NewsfilterVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
5.0
07-08NewsfilterVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9.0
07-08GlobenewswireGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Sign Up For More News
People Also Watch

ANIK
Anika Therapeutics Inc
11.000
USD
+2.90%

AOMR
Angel Oak Mortgage REIT Inc
9.590
USD
+2.24%

FF
FutureFuel Corp
4.130
USD
+1.47%

CLBR
Colombier Acquisition Corp II
16.850
USD
+1.62%

RAIL
FreightCar America Inc
11.320
USD
+5.30%

SVCO
Silvaco Group Inc
4.360
USD
+8.19%

TSBK
Timberland Bancorp Inc
32.300
USD
-0.09%

PKBK
Parke Bancorp Inc
21.970
USD
-0.27%

FET
Forum Energy Technologies Inc
19.150
USD
-0.26%

BWFG
Bankwell Financial Group Inc
38.010
USD
-0.11%
FAQ

What is Verastem Inc (VSTM) stock price today?
The current price of VSTM is 5.27 USD — it has increased 3.33 % in the last trading day.

What is Verastem Inc (VSTM)'s business?

What is the price predicton of VSTM Stock?

What is Verastem Inc (VSTM)'s revenue for the last quarter?

What is Verastem Inc (VSTM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Verastem Inc (VSTM)'s fundamentals?

How many employees does Verastem Inc (VSTM). have?
